Physician profile
Jaymin Patel
NPI 1831517598
$3,873.20
in general payments reported to CMS, 2019-2025
14 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $243 · 2021: $1,723 · 2022: $72.74 · 2023: $27.63 · 2024: $197 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,504.03 | 2019-2020 | |
| Inari Medical, INC. | $769.65 | 2021-2022 | |
| Edwards Lifesciences Corporation | $587.99 | 2020-2021 | |
| Cardiovascular Systems INC. | $217.14 | 2021-2022 | |
| Abiomed | $134.78 | 2025 | |
| Shockwave Medical, INC | $126.75 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Alnylam Pharmaceuticals INC. | $124.95 | 2024 | Amvuttra |
| Boston Scientific Corporation | $122.62 | 2021 | |
| Abbott Laboratories | $117.47 | 2021-2024 | Mitraclip |
| Biosense Webster, INC. | $66.47 | 2021 | |
| Terumo Medical Corporation | $27.63 | 2023 | Metacross Otw |
| Actelion Pharmaceuticals US, INC. | $26.95 | 2025 | Opsumit, Uptravi |
| Recor Medical INC | $25.67 | 2024 | Paradise Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaymin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.